Status:

UNKNOWN

The Value of 18F-FES-PET/CT in Predicting Fulvestrant Efficacy in Breast Cancer

Lead Sponsor:

First Affiliated Hospital Xi'an Jiaotong University

Conditions:

Estrogen Receptor-positive Breast Cancer

Fulvestrant

Eligibility:

FEMALE

18-65 years

Phase:

NA

Brief Summary

This study is focused on the value of 18F-FES-PET in predicting the Fulvestrant efficacy in hormone receptor-positive breast cancer. The imaging agent involved in this study is 16α-\[18F\]-fluoro-17β-...

Detailed Description

This study is an open, multi-center and prospective clinical study, It is the first time investigators are examining this imaging agent in Chinese patients with breast cancer. The Chinese FDA has app...

Eligibility Criteria

Inclusion

  • Be at least 18 years or older (required for legal consent)
  • Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%, see Appendix A)
  • Pathologically diagnosed metastatic breast cancer
  • Fulvestrant used as the first-line treatment
  • Have primary breast tumor that is at least 2 cm in diameter as measured in any dimension on either mammogram, ultrasound, or breast MRI
  • Have the ability to understand and the willingness to sign a written informed consent document.

Exclusion

  • General Exclusion Criteria
  • Previously treated metastatic breast cancer
  • Concurrent malignancy of any type
  • Impaired elimination (as defined as having problems with urination)
  • Participation in a research study/studies involving radiation exposure within the past 12 months
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, major kidney or liver disease, or psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnancy
  • Currently lactating (either breast feeding or breast pumping)
  • General PET/CT Safety

Key Trial Info

Start Date :

March 5 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2019

Estimated Enrollment :

68 Patients enrolled

Trial Details

Trial ID

NCT03768479

Start Date

March 5 2017

End Date

March 1 2019

Last Update

December 11 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China, 710061